Barclays raised the firm’s price target on Boston Scientific to $60 from $59 and keeps an Overweight rating on the shares. The company’s investor day highlighted its strong portfolio and pipeline, which positions Boston Scientific to exceed market growth across a range of end-markets, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BSX:
- Boston Scientific EVP Fitzgerald sells 15,867 common shares
- Boston Scientific price target raised to $64 from $62 at BTIG
- Boston Scientific sees organic sales growth of 8%-10% over three-year period
- Boston Scientific price target raised to $64 from $62 at Canaccord
- Boston Scientific price target raised to $61 from $58 at RBC Capital